Aims/hypothesis Although current literature suggests an association between diabetes and depression, the direction of the association is unclear. We examined the temporal association between diabetes and depression by studying antidepressant and benzodiazepine use around the initiation of diabetes treatment. Methods From a pharmacy registry database we selected 49,593 diabetic patients and a random sample of non-diabetic individuals (n=154,441), all >40 years old. Antidepressant and benzodiazepine use was calculated for the 7 years before and 7 years after the index date. The index date in diabetes patients was defined as the date of initiation of diabetes medication. A random index date was assigned to nondiabetic individuals. Time-specific incidence rate ratios of antidepressant and benzodiazepine use were calculated for intervals of 1 year, 3 months and 1 month. Results Antidepressant and benzodiazepine use was increased 2 months before and 3 months after the initiation of diabetes treatment compared with non-diabetic individuals.
Introduction
There is growing evidence that the prevalence of depression is increased among diabetic patients compared with persons without diabetes. A recent meta-analysis pooled ten crosssectional studies and reported an overall odds ratio of 1.8 [1] . However, the reason for this co-occurrence of diabetes and depression is not yet clear.
Depression may be a risk factor for developing diabetes. A pooled analysis of nine longitudinal studies showed a 1.4-fold increased risk of diabetes in depressed patients [2] . Two subsequently published longitudinal studies confirmed a significantly increased risk of onset of type two diabetes in depressed patients [3, 4] , whereas two other studies did not find an increased risk of diabetes in individuals older than 50 years [5] or in antidepressant users [6] .
Alternatively, diabetes might be a risk factor for onset of depression. Most longitudinal studies investigating this did not find a significant association between diabetes and incidence of depression [4, [7] [8] [9] [10] . A recent study among well-functioning older adults found an increased risk of recurrent depressed mood among diabetic patients [11] .
Despite the longitudinal design of these studies, they had some disadvantages. Most studies measured depression and diabetes only at two points in time with unknown events happening between these measurements. Only two studies that investigated depression as a risk factor for diabetes used incident cases of depression [6, 12] , while only three studies investigating diabetes as a risk factor for depression used incident cases of diabetes [8] [9] [10] . The selection of incident cases is preferable to the selection of prevalent cases as the exposed and unexposed groups are more comparable with regard to other characteristics. Moreover, none of the studies investigating diabetes as a risk factor for depression assessed the incidence of depression directly after diagnosis of diabetes, but instead measured depression at least 2 years after the diagnosis of diabetes. One study assessed the incidence of depression continuously over time but did not calculate time-specific incidence rates [9] . It is important to know when the risk of depression may be increased after a diagnosis of diabetes. To study this, depression should be continuously monitored.
The objective of our study was to investigate the temporal association between diabetes and depression by studying antidepressant and benzodiazepine use around the initiation of diabetes treatment. We studied antidepressant as well as benzodiazepine use in order to investigate whether the association with diabetes was specific for depression or whether diabetes was also related to more general psychosocial complaints.
Methods
Source population Our cohort was selected from the Pharmo database, as described in detail elsewhere [13] . In short, the database comprises all pharmacy dispensing records of residents of about 50 Dutch municipalities, accounting for approximately two million patient histories. Since virtually all patients in the Netherlands are registered with a single community pharmacy, pharmacy records are almost complete with regard to prescription drugs independent of the prescriber. In the Netherlands, antidepressants, benzodiazepines, oral hypoglycaemic agents and insulin are only available as prescription drugs. Therefore, pharmacy data will cover all use of these drugs. Variables included in the Pharmo database are sex, date of birth, dispensed drugs (coded according to the Anatomical Therapeutic Chemical Classification System), drug dispensing date, amount of drug dispensed, prescribed dosage regimen and type of prescriber.
Study population From the Pharmo database, we selected all patients who had a prescription of any glucose-lowering drug (Anatomical Therapeutic Chemical code A10A* and A10B*) between 1 January 1996 and 31 December 2006 and were born in 1965 or before, i.e. were older than 40 years on 31 December 2006 (n=97,667). We chose to only include individuals older than 40 years to make the samples of diabetic and non-diabetic individuals more comparable regarding age distribution. We randomly selected 195,334 persons (twice the sample size of the diabetic patients group) who were also older than 40 years at 31 December 2006 but did not have a prescription of any glucoselowering drug between 1 January 1996 and 31 December 2006. We aimed to include only incident diabetes cases in the study population. Therefore, we excluded individuals if their first recorded prescription of a glucose-lowering drug was within the first 6 months after entry into the Pharmo database, the date of entry being defined as the first known prescription of any medication (n=47,123). This was done because it was unclear whether these persons had already been diagnosed with diabetes before entering the Pharmo database. In the Netherlands, drugs are prescribed for a maximum period of 3 months. To be sure to exclude prevalent diabetes cases, we therefore chose 6 months as cut-off. The index date was defined as the initiation of glucose-lowering drug use in those prescribed glucoselowering drugs. Persons without a prescription for glucoselowering drugs were assigned a random index date in such a way that the distribution of the index dates relative to total follow-up time was similar to the distribution of the index dates relative to the total follow-up time in the diabetic patients. To ensure consistency, we excluded non-diabetic individuals if their index date was within the first 6 months after their first prescription in the Pharmo database (n= 26,364). Despite the restriction of only including persons older than 40 years at 31 December 2006, it was possible for some individuals to be younger than 40 years at the index date, as the index date was earlier than 31 December 2006 for virtually all individuals. We therefore excluded individuals who were younger than 40 years of age at the index date (diabetes n=821; non-diabetes n=14,169). Finally, a small number of individuals were excluded because of missing or incorrect antidepressant or benzodiazepine prescription data, for example a missing Anatomical Therapeutic Chemical code or extremely low (<1) or extremely high (>1,000) amounts of tablets dispensed with one prescription (diabetes n=130; non-diabetes n=240). This resulted in a study population of 49,593 diabetic patients and 154,441 non-diabetic patients to be analysed in this study.
Incidence of antidepressant and benzodiazepine use The start of an episode of antidepressant or benzodiazepine use was defined as the first prescription for any antidepressant (Anatomical Therapeutic Chemical code N06A*) or benzodiazepine (Anatomical Therapeutic Chemical code N05BA*, N05CD* or N05CF*) within the study period. The end of an episode of antidepressant or benzodiazepine use was defined as no new prescription of any antidepressant or benzodiazepine within 6 months after the end date of the last antidepressant or benzodiazepine prescription. The end date of a prescription was calculated by adding the duration of use (total amount dispensed divided by prescribed daily dose) to the start date of the prescription. The start of the first episode of antidepressant or benzodiazepine use was defined as incident, if a period of at least 6 months was present between the first known prescription in the Pharmo database and the start of the episode.
Covariates Age at index date, sex and the Chronic Disease Score were considered as covariates. The Chronic Disease Score is a measure of the chronic disease status among medication users and can be considered as an indicator of an individual's morbidity and overall health status. Exposure to various prescription drugs has been shown to be a valid measure of chronic diseases [14] . The Chronic Disease Score includes drugs used for the major chronic diseases such as heart disease, respiratory illness, cancer, ulcers and high cholesterol, and was calculated over the period of 1 year before the index date as a chronic disease measure at baseline.
Data-analysis
In theory, we had data from 11 years before the index date to 11 years after the index date, because we had prescription information from 1 January 1996 and 31 December 2006. However, because the number of individuals in the 7 to 11 years before and the 7 to 11 years after the index date was very small, we only analysed the time frame from 7 years before until 7 years after the index date.
We divided these 7 years before and after the index date into intervals of 1 year to investigate the pattern of incident antidepressant and benzodiazepine use over time. Within these 1 year intervals we calculated the number of incident antidepressant and benzodiazepine users and the amount of person-years contributing to these incident cases in diabetic and non-diabetic individuals. Cox regression was used to calculate incidence rate ratios and 95% CIs within each 1 year interval, adjusted for age, sex and the Chronic Disease Score. In this study, the incidence rate ratio represented the risk of a first antidepressant or benzodiazepine episode in diabetic patients relative to the non-diabetic individuals. To study the period around the index date in more detail, the 2.5 years before and after the index date were studied in intervals of 3 months. Finally, we studied the 10 months before and after the index date and divided this period into intervals of 1 month to have a detailed picture of the incidence rate ratios around the index date.
The part of the study before the index date can be seen as a case-control study with initiation of diabetes treatment as the outcome and incident antidepressant and benzodiazepine use as the exposure. Because of this case-control design, it may seem odd to calculate incidence rate ratios rather than odds ratios. We therefore repeated this part of the analysis using logistic regression instead of Cox regression and found similar results. In addition, we used incident cases from a dynamic source population and matched the controls to time by using a similar index date in cases and controls, enabling us to directly interpret our odds ratio as an incidence rate ratio as described in one of our previous papers [15] .
We also studied the impact of the possibly increased incidence of antidepressant and benzodiazepine use. Thus in patients with a first episode of antidepressant or benzodiazepine use after the index date, we compared the prevalence of antidepressant and benzodiazepine use between diabetic and non-diabetic patients using logistic regression. In addition, in patients with a first episode of antidepressant or benzodiazepine use after the index date, the length of the first episode of antidepressant and benzodiazepine use was compared between persons with and without diabetes. Table 1 gives the baseline characteristics of the study population. Diabetic patients were on average 6.6 years older than the non-diabetic individuals and were more often of male sex (48.9 vs 46.2%). Total follow-up time was slightly higher in diabetic patients. Almost 20% of the individuals had at least one antidepressant episode, while the proportion with more than one antidepressant episode was small (4.7%). Almost half of the individuals had at least one episode of benzodiazepine use and 19.8% had more than one episode. Both antidepressant and benzodiazepine episodes were more frequent among diabetic than among non-diabetic individuals.
Results
Examination of the 7 years before and 7 years after the index date showed that the incidence rate of antidepressant use was significantly increased in diabetic compared with non-diabetic individuals in the first year after the index date and was not increased in the other 1 year intervals (Fig. 1a) . Figure 1b presents a detailed part of the graph in Fig. 1a , showing 2.5 years before and 2.5 years after the index date. In Fig. 1c a detailed part of Fig. 1b is shown, covering 10 months before and 10 months after the index date. In the month before the index date the incidence rate of antidepressant use was increased in the diabetic patients compared with the non-diabetic patients (adjusted incidence rate ratio 1.42, 95% CI 1.14-1.78). In the first month after the index date the incidence rate ratio peaked, with a 2.4 fold increased incidence rate in diabetic patients. In the second and third month after the index date the incidence rate in the diabetic patients decreased again and was almost similar to that in the non-diabetic patients. Up until 2 years after the index date the prevalence of antidepressant use remained increased by at least 20% (OR>1.2) among patients with their first episode of antidepressant use after the index date (data not shown). The median duration of the incident episodes of antidepressant use after the index date was not significantly higher in diabetic patients (120 days) than in those without diabetes (114 days). Figure 2 presents the incidence rate ratios of benzodiazepine use in diabetic patients compared with non-diabetic individuals in 1 year intervals (Fig. 2a) , 3 month intervals (Fig. 2b) and 1 month intervals (Fig. 2c) . The incidence rate ratio of benzodiazepine use was increased 2 months before the index date (1.56, 95% CI 1.34-1.82). Similar to antidepressant use, the incidence rate ratio for benzodiazepine use peaked in the month after the index date (3.38, 95% CI 3.00-3.83) and decreased again in the second and third month after the index date. The prevalence of benzodiazepine use was increased by at least 20% (OR> 1.2) until 15 months after the index date among patients with their first episode of benzodiazepine use after the index date (data not shown). The median duration of the incident episodes of benzodiazepine use after the index date was significantly higher in diabetic patients (20 days) than in those without diabetes (15 days). The median duration of an episode of benzodiazepine use was markedly lower than the duration of an episode of antidepressant use. This is Table 2 presents more detailed information on the absolute and relative risks for antidepressant and benzodiazepine use in the 3 months before and after the index date.
Adjustment for age and sex did not substantially change the incidence rate ratios for antidepressant and benzodiazepine use, whereas additional adjustment for the Chronic Disease Score lowered the incidence rate ratios (Table 2) .
Discussion
We investigated the number of new users of antidepressants and benzodiazepines 7 years before and 7 years after the initiation of diabetes treatment. Both antidepressant and benzodiazepine use was only increased shortly before and shortly after starting diabetes treatment. A high peak in new use of these drugs by diabetic patients was seen especially in the first month after the index date with 2.4-and 3.4-fold increased incidence rates for antidepressant and benzodiazepine use, respectively. Although the new use of antidepressants and benzodiazepines was increased only shortly after the index date, the number of individuals continuing to use antidepressants and benzodiazepines was higher for up to 2 years and 15 months, respectively, after initiation of diabetes treatment.
Before interpreting the results, we will address some limitations of this study. We used antidepressant use as a proxy for depression. A limitation of this approach is that not all depressed patients are treated with antidepressants and that not all antidepressant users have an indication of depression [16] . However, more severe depression is likely to be recognised and treated [17] , and therefore antidepressant use may be a valid proxy for more severe and debilitating depression. Tricyclic antidepressants may also be prescribed for diabetic neuropathy. To check whether this explained the high incidence of antidepressant use, we performed an additional analysis in which patients using tricyclic antidepressants (35.2% of all patients using antidepressants) were excluded. This resulted in somewhat smaller incidence rate ratios (for example the incidence rate ratio at 1 month after the index date decreased from 2.43 to 2.35), but the trend over time clearly remained, suggesting that antidepressant use for diabetic neuropathy did not explain our results.
Benzodiazepine use was used as a proxy for more general psychosocial complaints. Insomnia and anxiety are the main indications for benzodiazepine use, but in practice benzodiazepines are prescribed more broadly for indications related to psychosocial problems [18] . We therefore consider benzodiazepine use to be a good proxy for general psychosocial complaints.
Another possible limitation of our study is that we measured diabetes as initiation of diabetes medication. For that reason we missed undiagnosed diabetic patients and misclassified diabetic patients not receiving pharmacological agents as being nondiabetic patients. Therefore, the start of diabetes medication might lag behind the diagnosis of diabetes. Consequently, the increased use of antidepressants and benzodiazepines we observed before the index date could actually be a consequence, and not a cause, of already existing, but not yet diagnosed or pharmacologically treated, diabetes. In addition, the categorisation of diabetic patients not being treated with pharmacological agents as non-diabetic patients could have resulted in an underestimation of the true effects.
A limitation regarding confounding is that we adjusted for age, sex and the Chronic Disease Score in the analyses, but had no information on other possible confounders such as BMI and physical inactivity. Assuming that higher BMI and physical inactivity are associated with increased risk of depression and increased risk of diabetes, we could have overestimated the true relation between depression and diabetes. However, for two reasons, this is unlikely to explain all of the effect we found. First, adjustment for age, sex and especially the Chronic Disease Score will already have captured some of the effects that other confounders might have had and therefore additional adjustment for other confounders probably would not have had a very large effect. Second, previous studies that investigated the association between depression and diabetes, and adjusted for many confounders showed a maximal change of their age-and sex-adjusted effect estimate of 26% [2, 19] . The effect that we showed was quite large, especially in the month after initiation of diabetes treatment, and a reduction of 26% would still leave a considerable effect size.
An important strength of this study is that information on antidepressant and benzodiazepine use was available at every point in time. This gave us the opportunity to calculate time-specific incidence rates of antidepressant and benzodiazepine use with a view to studying the association between depression and diabetes in detail and within one study population. Moreover, we were able to study a large population, as we had the complete prescription history of almost 50,000 diabetic patients and 150,000 non-diabetic patients.
This study showed an increased incidence of antidepressant and benzodiazepine use shortly after the initiation of diabetes medication. This suggests that diabetes has no long-lasting effect on depression or psychosocial complaints. Other studies that assessed incidence of depression after diagnosis of diabetes calculated this after a period of at least 2 years [8] [9] [10] and therefore may have missed the increased incidence shortly after diagnosis. The increased use of antidepressants and benzodiazepines could be a consequence of the burden of diabetes, as was noticed in previous papers [20] [21] [22] . It is also possible that it reflects selective detection by the physician. For instance, the physician may be more likely to detect depressive or psychosocial complaints in patients consulting their physician for diabetes-related complaints, simply because of the contact between physician and patient, or because the physician had the perception that the patient might benefit from an antidepressant or benzodiazepine after receiving bad news, i.e. diagnosis of diabetes.
This study also showed an increased incidence of antidepressant and benzodiazepine use shortly before the initiation of diabetes medication. There are several possible explanations for this finding. First, depression and psychosocial complaints might be risk factors for diabetes. Indeed, several previous longitudinal studies have shown that depression increased the risk of developing diabetes [2] [3] [4] . Second, antidepressants themselves might be a risk factor for diabetes, as the literature indicates that antidepressant use can disturb glucose levels and glycaemic control [23] . However, the short time period we observed between the increased incidence of antidepressant and benzodiazepine use and the initiation of diabetes treatment makes it unlikely that depression, psychosocial complaints or anti- Table 2 Incidence rates, and crude and adjusted incidence rate ratios (95% CIs), in non-diabetic individuals and diabetic patients (per 1,000 person-years) for antidepressant and benzodiazepine use in the 3 months before and after the index date depressants are causal risk factors for diabetes. As a third explanation, the increased incidence before the index date could in fact be a consequence, rather than a cause, of being diagnosed with diabetes, because the start of diabetes medication could be later than the actual date of diagnosis of diabetes. A fourth explanation of our findings could be that diabetes was more likely to be diagnosed in patients being treated with antidepressants or benzodiazepines. This higher detection of diabetes could have led to an overestimation of the association.
In contrast to other studies [2] [3] [4] , our results do not indicate that depression is a causal risk factor for diabetes. Our study design differed in two aspects from these studies. We compared patients without depression and patients with new depression, rather than patients with already existing depression. This is important because, regarding certain confounders, patients with new depression will be more comparable to those without depression than patients with already existing depression. Studying patients with new depression therefore leads to more comparable groups regarding confounders, with less chance of residual confounding and therefore more valid results. Another factor in which our study contrasts with other studies is that we measured depression continuously over time, which might lead to a better representation of depression than when depression is assessed at one point in time.
We studied antidepressant use as well as benzodiazepine use to investigate whether the association with diabetes was specific for depression or whether diabetes was also related to more general psychosocial complaints. The similar findings for antidepressant and benzodiazepine use suggest that the association with diabetes is not specific to depression and that diabetes is also associated with more general psychosocial complaints.
In conclusion, this study showed an increased incidence of antidepressant and benzodiazepine use shortly before and shortly after the initiation of diabetes medication. This may be a consequence of being diagnosed with diabetes or starting with diabetes medication. It could, however, also reflect earlier detection by their physician.
